GREENFIRE BIO
Greenfire Bio operates as a life science development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by developing early-stage assets through proof of concept and investing in unique medical breakthroughs. Greenfire typically licenses, acquires, partners, or invests in differentiated pre-clinical or early clinical-stage programs to bridge the translational medicine gap and accelerate development.
GREENFIRE BIO
Social Links:
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-06-02 | Pacylex | Greenfire Bio investment in Series A - Pacylex | N/A |
More informations about "Greenfire Bio"
Greenfire Bio - Crunchbase Investor Profile & Investments
Greenfire Bio operates as a life science development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by developing early-stage assets through proof of concept and investing in unique medical breakthroughs. โฆSee details»
Greenfire Bio - LinkedIn
Greenfire Bio is a diversified life science company led by a team of experienced business and development executives building a product portfolio by addressing the chronic mismatch between ...See details»
Greenfire Bio investment portfolio - PitchBook
Greenfire Bio General Information Company Description. Greenfire Bio is a development and investment company. The company licenses, acquires, partners, or invests in differentiated โฆSee details»
Greenfire Bio - BioCentury Company Profiles - BCIQ
Greenfire Bio - BioCentury Company Profiles for the biopharma industrySee details»
Markus Peter - VP Program Lead - Greenfire Bio
VP Program Lead at Greenfire Bio · Global Program Management Leader with 20 years of industry experience including over 14 years of management for drug development and commercialization programs.See details»
Ajit Gill - President & CEO - MGFB Corp - LinkedIn
President & CEO Greenfire Bio LLC · Experienced CEO in bio-pharmaceuticals. Also involved with several life science start-ups in the US and India. · Experience: MGFB Corp · Education: โฆSee details»
Greenfire Bio Fund Manager Profile | Preqin
Greenfire Bio is an investment company that focuses on innovative products to improve patients' lives and medical outcomes. Read more Show less. Asset Class No. of Funds Currently โฆSee details»
BioCentury - MGFB: vaccinating against tumor antigen escape
Nov 16, 2022 MGFB is developing virus-based cancer vaccines for solid tumors that prime the immune system against hundreds of tumor antigens, including ones that arise during tumor โฆSee details»
Greenfire Bio LLC - Drug pipelines, Patents, Clinical trials - Synapse
Explore Greenfire Bio LLC with its drug pipeline, therapeutic area, technology platform, 5 news, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, Immune System โฆSee details»
Green3Bio Announces Publication of Pre-Clinical Data โฆ
FRISCO, Texas, June 24, 2022 /PRNewswire/ -- Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation 1 led by researchers at The โฆSee details»
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2 ...
FRISCO, Texas, May 31, 2022 /PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an โฆSee details»
Chris Searcy - Chief Corporate Development Officer - Greenfire Bio โฆ
CCDO · Experience: Greenfire Bio and MGFB · Location: Lexington · 500+ connections on LinkedIn. View Chris Searcyโs profile on LinkedIn, a professional community of 1 billion members.See details»
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2 ...
May 31, 2022 Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022. News provided by. Greenfire โฆSee details»
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2 ...
FRISCO, Texas, May 31, 2022 /PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an โฆSee details»
Evaluation of bi-layer silk fibroin grafts for onlay urethroplasty in a ...
Aug 30, 2024 This study was supported by WeaveTech, Subsidiary of Greenfire Bio Corporation. The authors have no other relevant affiliations or financial involvement with any โฆSee details»
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2 ...
FRISCO, Texas, May 31, 2022 /PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an โฆSee details»
greenfire bio News & Press Releases - PR Newswire
May 31, 2022 News from greenfire bio A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, โฆSee details»
Greenfire Bio - Company Profile - Tracxn
Oct 19, 2024 Greenfire Bio ranks 6th among 6 active competitors. 3 of its competitors are funded Overall, Greenfire Bio and its competitors have raised over $49.1M in funding across 5 โฆSee details»
Greenfire Bio - Founders and Board of Directors - Tracxn
Jul 23, 2024 Greenfire Bio founders & board of directors. Developer of therapeutic solutions for the treatment of ovarian cancer. 2020 โข United States โข UnfundedSee details»
Yury Borisov - Wikipedia
Yury Ivanovich Borisov (Russian: ะฎัะธะน ะะฒะฐะฝะพะฒะธั ะะพัะธัะพะฒ; born 31 December 1956) is a Russian politician, former military strategist, and mathematician currently serving as General โฆSee details»